
Overview
Genxone is a laboratory specializing in next generation sequencing (NGS) and molecular diagnostics, utilizing nanopore sequencing technology developed by Oxford Nanopore Technologies. It offers a range of sequencing services, including metagenomic sequencing, 16s and/or ITS gene sequencing, and whole genome sequencing. Additionally, Genxone provides custom-designed analysis and bioinformatics services.
Financials
Revenue history (in k)
From the notes
| Current income tax (CIT due) | $0 |
Filing timeliness
Financial statements were filed on time, on average 32 days early. All were audited by a statutory auditor.
- 202526/06/2026
- 202425/06/2025
- 202326/06/2024
- 202222/06/2023
- 202117/06/2022
- 202027/07/2021
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Stock quotes
- Open
- PLN 4.58
- High
- PLN 4.58
- Low
- PLN 4.58
- Volume
- 3
- Avg. vol.
- 706
- Market cap
- PLN 15.14M
- P/E ratio
- –
- EPS
- -PLN 0.43
- Shares outstanding
- 3.3M
- 52-week
- PLN 4.50 – 5.38
- Dividend yield
- 21.83%
- Dividend
- PLN 1.00
- Ex dividend date
- Jun 16, 2022
- ISIN
- PLGENXN00013
- Exchange
- NewConnect
Quarterly results
| Period | Revenue | EBIT | Net profit |
|---|---|---|---|
| Q3 2026 | USD 176.39k | USD -129.93k | USD -125.34k |
| Q2 2026 | USD 153.16k | USD -94.27k | USD -88.87k |
| Q1 2026 | USD 132.63k | USD -145.60k | USD -139.65k |
| Q4 2025 | USD 230.29k | USD -57.76k | USD -49.22k |
Statistics
How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.
Results vs industry
News
Industry
Websites
- nanobiome.plNanobiome – polskie badanie mikrobioty jelitowejWooCommerce 8.1WordPress 6.3ElementorGoogle AdsGoogle AnalyticsGoogle Tag Manager
Public procurement
7 tenders recorded as contractor, with a total value of $384,416.
| Publication date | Subject | Amount | Contracting authority | |
|---|---|---|---|---|
| Jun 25, 2026 | Comprehensive microbiome next-generation sequencing service | $66,647$66,647 | Narodowy Instytut Geriatrii,Reumatologii I Rehabilitacji Im. Prof. Dr Hab. Med. Eleonory Reicher | |
| Dec 3, 2025 | Successive supply of chemical reagents and microbiological materials under a framework agreement for Wojewódzka Stacja Sanitarno-Epidemiologiczna w Rzeszowie | $36,029$36,029 | Wojewódzka Stacja Sanitarno - Epidemiologiczna w Rzeszowie | |
| Oct 1, 2025 | Purchase of a system for analyzing bacterial antibiotic resistance genes, including the lease of a nanopore next-generation sequencing device for UCK. | $59,959$59,959 | Uniwersyteckie Centrum Kliniczne |
The company is the contractor in 4 public sector contracts, worth USD 8.62k in total. They were signed with 3 public buyers.
| Signed on | Subject | Amount | Public buyer | |
|---|---|---|---|---|
| Nov 4, 2026 | Reagents | $675.31 | Uniwersytet Marii Curie-Skłodowskiej | |
| Sep 30, 2026 | Long-read genetic service, sequencing service for 2 bacterial genomes using the method | $636.88 | Uniwersytet Marii Curie-Skłodowskiej | |
| Jul 23, 2026 | Bacteriophage genome sequencing service. | $2,566 | Instytut Immunologii I Terapii Doświadczalnej Im.Ludwika Hirszfelda Pan we Wrocławiu |
Authorized Representatives
Manner of representation
If one member of the management board has been appointed, that member is entitled to independently represent the company. If a multi-member management board has been appointed, the company shall be represented individually by each member of the management board.
Supervisory board
Beneficial owners
| Person | Rights |
|---|---|
Bank accounts
Registered as a VAT taxpayer on 2016-11-17.
93 2490 0005 0000 4600 3535 5349
68 2490 0005 0000 4600 3627 9821
37 2490 0005 0000 4600 3410 1856
Debt
No entries in the National Debtors Register (KRZ).
Real estate
| Type | Amount |
|---|---|
Buildings and premises | PLN 11,896PLN 11,896 |
MSiG notices
6 notices recorded in the Court and Commercial Gazette (MSiG).
| Publication date | Event | |
|---|---|---|
| Jun 18, 2020 | Shareholders' meeting convened | |
| Feb 26, 2020 | Shareholders' meeting convened | |
| Dec 19, 2019 | Commercial Companies Code notice | |
| Nov 12, 2019 | Commercial Companies Code notice | |
| Nov 4, 2019 | Call to creditors |
Public aid
9 public aid cases recorded, with a total value of $1,118,093.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Sep 21, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | $10,556$10,556 | Prezes Zakładu Ubezpieczeń Społecznych | |
| Sep 21, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | $5,538$5,538 | Prezes Zakładu Ubezpieczeń Społecznych | |
| May 30, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | $5,542$5,542 | Prezes Zakładu Ubezpieczeń Społecznych |
European Funds
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2018-03-01 | Development of an innovative test for diagnosing postoperative wounds using next-generation sequencing (NGS) technology. | $912K$912,022 | Operational Programme Smart Growth | |
| 2018-02-01 | Preparation of documentation to obtain external financing for GENXONE Sp. z o.o. through a share issue and their debut on the NewConnect market of GPW w Warszawie | $27,398$27,398 | Operational Programme Smart Growth |
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
| BDO register entry | Active |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Toxlab sp. z o.o. | $865,185.14 | toxlab.pl | ||
| Zakład Genetyki Sądowej sp. z o.o. | $727,654.12 | dna-zgs.pl | ||
| Polbiotech Laboratorium sp. z o.o. | $645,943.81 | polbiotech.pl | ||
| Precisionlife Poland sp. z o.o. | $617,020.34 | precisionlife.com | ||
| Camino Science sp. z o.o. | $557,065.18 | camino.science | ||
| Vaxican sp. z o.o. | $390,933.79 | vaxican.com | ||
| Rivbio sp. z o.o. | $266,377.70 | rivbio.com | ||
| Seqme S.R.O. Branch (foreign co.) | $247,214.49 | seqme.eu | ||
| Nexbio sp. z o.o. | $186,582.40 | nexbio.pl | ||
| Intelliseq S.A. | $156,552.76 | intelliseq.pl |
Change history
| Date | Event | |
|---|---|---|
| 2024-07-19 | Share capital increase (3,296,600.00 PLN → 3,304,820.00 PLN) | |
| 2023-07-27 | Share capital increase (3,295,000.00 PLN → 3,296,600.00 PLN) | |
| 2020-06-15 | Share capital increase (2,695,000.00 PLN → 3,295,000.00 PLN) | |
| 2019-09-17 | Share capital increase (2,389,000.00 PLN → 2,695,000.00 PLN) | |
| 2019-06-19 | Share capital increase (2,039,000.00 PLN → 2,389,000.00 PLN) |
FAQ
Last updated: 2026-07-09



